Dermatologists.com

Vendor directory

Bristol Myers Squibb

Bristol Myers Squibb lists SOTYKTU (deucravacitinib) for adults with moderate to severe plaque psoriasis who may benefit from systemic therapy or phototherapy. The company's prescribing information describes two clinical trials, PSO-1 and PSO-2, evaluating the medicine. Bristol Myers Squibb's dermatology materials also include information for healthcare professionals and patients about the product. The U.S. prescribing information identifies the dose used in those studies as 6 mg once daily. Product materials include patient information as well as prescribing details for clinicians.

Richard C. Wilson

Backed by Richard C. Wilson and Family Office Club, the largest investor club in the world by media reach

  • $1B+In deals closed between members
  • 17MRegistered members across our networking groups
  • 19MSocial media followers
  • 340+Events hosted since 2007
  • 16In-person events a year
  • 50AI tools built on what works with family offices and investors

Family Office Club network figures. They describe the organization and its members, not a promise of investment or transaction results.